(VDRE). 2 VDR belongs to the nuclear receptor superfamily for steroid hormones, retinoic acid, and thyroid hormone (T 4 ). 3 These receptors bind to their responsive elements and alter downstream gene transcription. In addition, 1␣,25-(OH) 2 D 3 has also been shown to produce rapid, nongenomic (ie, VDRE-independent) responses. 4 Indeed, 1␣,25-(OH) 2 D 3 stimulates a wide array of rapid responses including rapid intestinal absorption of calcium (transcaltachia), 5 store-operated calcium influx, 6 activation of protein kinase C, 7 and opening of voltage-gated calcium and chloride channels. 8 Although the precise molecular mechanisms by which these rapid nongenomic responses are regulated remain unclear, a putative membrane receptor for 1␣,25-(OH) 2 D 3 or alternative pathways of the nuclear VDR have been proposed. 9 Analogs of 1␣,25-(OH) 2 D 3 have been used to differentiate the genomic (ie, VDRE-dependent) versus nongenomic responses. These analogs take advantage of the flexible conformation of 1␣,25-(OH) 2 D 3 at the 6,7 carboncarbon single bond (Figure 1). Rapid rotation about this bond allows generation of a continuum of various shapes of 1␣,25-(OH) 2 D 3 ranging from the planar extended 6-s-trans conformation to the steroid-like 6-s-cis conformation 10,11 ; these various shapes are then available to serve as ligands for appropriate receptors. Indeed, the 6-s-cis-locked analog 1␣,25-dihydroxylumisterol is a fully potent agonist of rapid, nongenomic responses of 1␣,25-(OH) 2 D 3 . 5 Thus, it has been proposed that different shapes of the conformationally flexible 1␣,25-(OH) 2 D 3 are agonists for the rapid, nongenomic (6-s-cis) and genomic (twisted 6-s-trans) responses. 12 In addition, analogs that antagonize 1␣,25-(OH) 2 D 3 responses have also been characterized. Indeed, 1,25-(OH) 2 D 3 (HL) is a specific antagonist of nongenomic action of 1␣,25-(OH) 2 D 3 , 8,13 whereas (23S)-25-dehydro-1␣-OH-D 3 -26,23-lactone (MK) preferentially inhibits genomic responses. 14 Original